Inactive Instrument

Neurotrope, Inc.

Equities

NTRP

US64129T2078

Neurotrope, Inc. Announces Resignation of Andrew Perlman as Board of Director

June 22, 2018 at 04:30 pm EDT

Neurotrope, Inc. announced Andrew Perlman resigned as a member of the Board of Directors of the company. Mr. Perlman's resignation was not a result of any disagreement with the company on any matter relating to the company's operations, policies or practices.

Latest news about Neurotrope, Inc.

Neurotrope, Inc. completed the spin-off of Neurotrope Bioscience, Inc.	20-12-01	CI
Metuchen Pharmaceuticals LLC completed the acquisition of Neurotrope, Inc. from Intracoastal Capital LLC and others in a reverse merger transaction.	20-11-30	CI
Neurotrope, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2020	20-11-09	CI
Neurotrope, Inc Announces Dosing of the First Patient in Its Ongoing, Long-Term Phase 2 Study of Bryostatin-1 for the Treatment of Alzheimer's Disease	20-10-06	CI
Neurotrope, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2020	20-08-10	CI
Neurotrope, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020	20-06-12	CI
Bryologyx Announces Agreements with Neurotrope to Acquire Bryostatin-1 Immuno-Oncology Data Package, Supply Synthetic Bryostatin-1	20-06-10	CI
Neurotrope, Inc. Launches New Long-Term Clinical Trial of Bryostatin with the National Institutes of Health for the Treatment of Patients with Alzheimer's Disease	20-05-28	CI
Metuchen Pharmaceuticals LLC entered into a non-binding term sheet to acquire Neurotrope, Inc. from Intracoastal Capital LLC and others for approximately $140 million in a reverse merger transaction.	20-05-17	CI
Neurotrope, Inc. intends to spin off Neurotrope Bioscience, Inc.	20-05-16	CI
Neurotrope, Inc. Reports Earnings Results for the Full Year Ended December 31, 2019	20-03-13	CI
Neurotrope, Inc. Announces Board Resignations	20-02-27	CI
Neurotrope Provides Corporate Update After Completing Bryostatin-1 Data Analysis for Advanced Alzheimer's Disease Trial	20-01-22	CI
National Institute of Health Awards $2.7 Million Grant to Neurotrope	20-01-22	CI
Neurotrope, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2019	19-11-12	CI
Neurotrope Reviews Strategic Alternatives to Maximize Shareholder Value	19-10-08	CI
Neurotrope, Inc. Announces Top-Line Results from Confirmatory Phase 2 Study of Bryostatin-1 in Moderate to Severe Alzheimer's Disease	19-09-09	CI
Neurotrope, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2019	19-08-08	CI
Neurotrope Concludes Data Collection in Confirmatory Phase 2 Clinical Trial of Moderately Severe to Severe Alzheimer's Disease	19-07-15	CI
Neurotrope, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2019	19-05-09	CI
Neurotrope, Inc. Appoints Michael Ciraolo as General Counsel and Chief Operating Officer	19-04-01	CI
Neurotrope Inc Comments on Biogen's Discontinued Phase 3 Trial in Alzheimer's Disease	19-03-21	CI
Neurotrope Inc. Completes Enrollment of Confirmatory Phase 2 Study of Bryostatin-1 in Moderate to Severe Alzheimer's Disease	19-03-13	CI
Neurotrope, Inc. Reports Earnings Results for the Full Year Ended December 31, 2018	19-03-08	CI
Neurotrope Announces Cooperative Research and Development Agreement for Bryostatin-1 with the National Cancer Institute	19-02-04	CI

Chart Neurotrope, Inc.

Duration

Period

More charts

Company Profile

Neurotrope, Inc., is a biopharmaceutical company with its product candidates in pre-clinical and clinical development. The Company is focused on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer's disease (AD), which is in the clinical testing stage. Bryostatin, which is a protein kinase C (PKC) Alpha and e activator, is also developed for other neurodegenerative or cognitive diseases and dysfunctions, which are in pre-clinical testing. Its second-generation PKC activators, such as the Bryologs are meant for the treatment of central nervous system disorders, lysosomal storage diseases, stroke, cardio protection and traumatic brain injury. It develops Bryostatin-1 for the treatment of Alzheimer's disease along with the rare (Orphan) diseases, such as Fragile X Syndrome and Niemann-Pick Type C.

Sector

More about the company